Dendreon jumps on 'heavyweight' board appointments

Tools

Few vaccine companies get a big bump in their stock prices when they add members to their boards. But you don't often get "heavyweight gunslingers" like these. Dendreon, which is nearing an NDA for Provenge, announced that Genentech CEO Ian Clark and Pedro Granadillo, who had been Eli Lilly's top manufacturing aficionado, are coming on board. And investors bid up their shares by eight percent. Dendreon release | Report

Filed Under

Comments